Hydroxyurea: The Treatment for Sickle Cell Anemia and Cancer
What is Hydroxyurea?
Hydroxyurea is a chemotherapeutic agent used in patients of sickle cell anemia, certain cancers (like leukemia), and to prevent recurrences of pain crisis. It works by increasing production of Hb F thereby decreasing prevalence of sickling and pain crisis.
How Hydroxyurea Works
Hydroxyurea increases the production of hemoglobin F, a form of hemoglobin present in fetuses that helps prevent red blood cells from sickling. In cancer, it interferes with the growth and spread of cancer cells by inhibiting DNA synthesis.
When to Use Hydroxyurea
● Sickle Cell Anemia: To reduce the frequency of painful crises and complications related to sickle cell anemia.
● Cancer: Used in certain types of cancer, such as chronic myelogenous leukemia (CML) and polycythemia vera.
● HIV-Related Complications: Used off-label for HIV treatment in combination with other drugs.
Dosage
● Adult Dose for Sickle Cell Anemia: Typically starts at 15 mg/kg/day, and the dose is gradually adjusted.
● Cancer Treatment: Dosage varies based on the cancer type, often starting at 20 mg/kg/day once daily. Maximum dose goes upto 35 mg/kg/day.
Side Effects
● Nausea, vomiting, bone marrow suppression (low blood cell counts), skin ulcers, and liver toxicity.
Common Brands in India: Hydrea, Droxia, Durea.
FAQ
How does Hydroxyurea help with sickle cell anemia?
It increases the production of fetal hemoglobin, which prevents red blood cells from sickling and improves blood flow.
Can Hydroxyurea be used for cancer?
Yes, it is used in the treatment of cancers like leukemia, as it inhibits cancer cell growth.
Are there long-term risks with Hydroxyurea?
Long-term use can lead to bone marrow suppression, so regular monitoring is required.
Disclaimer
Hydroxyurea should only be used under the supervision of a healthcare provider due to potential side effects. HealthPil provides access to hematologists and oncologists for optimal management of sickle cell disease and cancer treatment.
